Clinical trials: Semaglutide, completed
Diabetes Mellitus, Type 2
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes.
- Trial name
- FLOW (NCT03819153)
- Testing
- Semaglutide
- Where
- 413 sites in United States, Argentina and 26 more
- Volunteers
- 3,533 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Metabolism and Nutrition Disorder
Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo
This trial is conducted in Europe. The aim of the trial is to investigate the effect of semaglutide on energy intake, appetite sensations, postprandial glucose and triglyceride metabolism and gastric emptying in obese subjects…
- Conditions
- Diabetes, Metabolism and Nutrition Disorder, Obesity
- Trial name
- NCT02079870
- Testing
- semaglutide
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity, Bariatric Surgery
SEMASEARCH, Retrospective/Prospective Cohort Nested at ATUc/AP2 WEGOVY®
The aim of the SEMASEARCH project is therefore to constitute a retrospective cohort, from the available data on patients already included in the ATUc/AP2, and prospective, on new patients who will initiate treatment according to…
- Conditions
- Obesity, Bariatric Surgery, Binge Eating Disorder, Syndromic Obesity
- Trial name
- SEMASEARCH (NCT05897398)
- Testing
- Data collection, Blood sampling, Questionnaires
- Where
- 14 sites in France
- Volunteers
- 1,100 people
- Sponsor
- Hospices Civils de Lyon
Diabetes, Diabetes Mellitus, Type 2
Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes
This clinical trial is conducted in Europe. The purpose of the trial is to investigate the influence on the pharmacokinetics (the rate at which the trial drug is eliminated from the body) of an oral contraceptive combination drug…
- Trial name
- NCT01324505
- Testing
- semaglutide, Microgyn®
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- Novo Nordisk A/S
Non-alcoholic Steatohepatitis
A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage
Semaglutide is a medicine studied in patients with non-alcoholic steatohepatitis (NASH), as it may improve liver damage. Participants will either get semaglutide or placebo (a dummy medicine) - which treatment participants get is…
- Trial name
- NCT03987451
- Testing
- Semaglutide
- Where
- 38 sites in United States, France and 3 more
- Volunteers
- 71 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide once weekly versus placebo as add-on to basal insulin alone or basal…
- Trial name
- SUSTAIN™ 5 (NCT02305381)
- Testing
- semaglutide
- Where
- 99 sites in United States, Germany and 4 more
- Volunteers
- 397 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People
In this study a known investigational medicinal product called semaglutide will be tested in four different tablet versions. In addition to semaglutide, the different tablet versions C, D, E and F contain different helping agents…
- Trial name
- NCT04524832
- Testing
- Oral semaglutide
- Where
- Germany
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of the trial is to investigate the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes.
- Trial name
- PIONEER 6 (NCT02692716)
- Testing
- semaglutide
- Where
- 228 sites in United States, Algeria and 19 more
- Volunteers
- 3,183 people
- Sponsor
- Novo Nordisk A/S
Type2diabetes
Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants
This is a Phase 1b, randomized, open-label, active-controlled, parallel, multiple-dose study comparing the safety, pharmacokinetics and efficacy of DehydraTECH Cannabidiol and Glucagon-like Peptide 1 (GLP-1) agonists alone and in…
- Trial name
- DehydraTECH (NCT06648031)
- Testing
- Arm 1 - DehydraTECH-CBD alone, Arm 2 - DehydraTECH-semaglutide alone, Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide
- Where
- 7 sites in Australia
- Volunteers
- 148 people
- Sponsor
- Lexaria Bioscience Corp.
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe, North and South America. The aim of the trial is to compare the effect of once-weekly (OW) dosing of subcutaneous semaglutide (1.0 mg) versus once-daily dosing of oral…
- Trial name
- SUSTAIN 8 (NCT03136484)
- Testing
- Semaglutide, Canagliflozin
- Where
- 119 sites in United States, Argentina and 10 more
- Volunteers
- 788 people
- Sponsor
- Novo Nordisk A/S
Alcohol Use Disorder
Semaglutide Therapy for Alcohol Reduction - Tulsa
The purpose of this research study is to determine if semaglutide, when compared to placebo, is safe and may reduce alcohol drinking in individuals who endorse symptoms consistent with alcohol use disorder.
- Trial name
- STAR-T (NCT05891587)
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Oklahoma State University Center for Health Sciences
Overweight, Obesity
STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity
This study will look at the change in participants' body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Trial name
- STEP 6 (NCT03811574)
- Testing
- Semaglutide
- Where
- 28 sites in Japan, South Korea
- Volunteers
- 401 people
- Sponsor
- Novo Nordisk A/S
HIV/AIDS, Lipohypertrophy
Effects of Semaglutide in HIV-Associated Lipohypertrophy
This is a randomized, double-blinded, placebo-controlled trial designed to assess the effect of the GLP-1 receptor agonist, semaglutide, on visceral and ectopic fat, insulin resistance, inflammation markers, and the downstream…
- Conditions
- HIV/AIDS, Lipohypertrophy, Obesity
- Trial name
- NCT04019197
- Testing
- Semaglutide Injectable Product
- Where
- 2 sites in United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Case Western Reserve University
Diabetes Mellitus, Type 2
Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes
The goal of this observational retrospective study is to understand whether glucagon-like peptide-1 receptor agonists (GLP-1RA), which are a group of antidiabetes drugs, may act differently in different subtypes of patients with…
- Trial name
- NCT06120556
- Testing
- GLP-1 receptor agonist
- Where
- Italy
- Volunteers
- 130 people
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Diabetes, Diabetes Mellitus, Type 2
Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects
This trial is conducted in Europe and Asia. The aim of the trial is to investigate the influence of semaglutide on pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02022254
- Testing
- semaglutide, metformin, warfarin
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by the study doctor. The study will last for about 6 to 8 months.
- Trial name
- NCT03631186
- Testing
- Semaglutide
- Where
- 28 sites in Switzerland
- Volunteers
- 215 people
- Sponsor
- Novo Nordisk A/S
Overweight and Obesity
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity
Novo Nordisk are doing this study to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight. This study will look at the change in participants' body weight.
- Trial name
- OASIS 2 (NCT05132088)
- Testing
- semaglutide 50 mg
- Where
- 15 sites in Japan, South Korea
- Volunteers
- 201 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.
This study is a randomized, open-label, single-dose, parallel-controlled biosimilar comparison study comparing the pharmacokinetics, safety and immunogenicity of the investigational drug and the active comparator in healthy adult…
- Trial name
- NCT06634927
- Testing
- Ozempic®, HDG1901
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
This study will look at how participants' daily life is affected by their heart failure. The study will also look at the change in participants' body weight.
- Trial name
- STEP HFpEF DM (NCT04916470)
- Testing
- Semaglutide
- Where
- 180 sites in United States, Argentina and 14 more
- Volunteers
- 617 people
- Sponsor
- Novo Nordisk A/S
Overweight and Obesity, Type2diabetes
Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant
The purpose of this study is to evaluate the safety, tolerability and drug levels of an exenatide implant administered subcutaneously.
- Trial name
- LIBERATE-1 (NCT05670379)
- Testing
- Exenatide Implant, Bydureon BCise (exenatide extended release), Semaglutide, 1.0 mg/mL
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vivani Medical, Inc